Equine AGP antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-EQU-AGP-Ag01	Recombinant Equine AGP protein	3090
GMP-EQU-AGP-Ab01	Anti-Equine AGP mouse monoclonal antibody (mAb)	1953
GMP-EQU-AGP-Ab02	Anti-Equine AGP mouse monoclonal antibody (mAb)	1953
GMP-EQU-AGP-Ab03	Anti-Equine AGP human monoclonal antibody (mAb)	1953
GMP-EQU-AGP-Ab04	Anti-Equine AGP human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-EQU-AGP-Ag01
Product Name	Recombinant Equine AGP protein
Target/Biomarker	Equine Alpha-1-acid glycoprotein (AGP)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine Alpha-1-acid glycoprotein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AGP level test of animal Equine/Horse with Systemic Inflammation.
Tag	His
Products description	Recombinant Equine AGP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-AGP-Ab01, GMP-EQU-AGP-Ab02
Product Name	Anti-Equine AGP mouse monoclonal antibody (mAb)
Target/Biomarker	Equine Alpha-1-acid glycoprotein (AGP)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine Alpha-1-acid glycoprotein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies in AGP level test of animal Equine/Horse with Systemic Inflammation.
Tag	mFc
Products description	Anti-Equine AGP mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-AGP-Ab03, GMP-EQU-AGP-Ab04
Product Name	Anti-Equine AGP human monoclonal antibody (mAb)
Target/Biomarker	Equine Alpha-1-acid glycoprotein (AGP)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Equine Alpha-1-acid glycoprotein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies in AGP level test of animal Equine/Horse with Systemic Inflammation.
Tag	hFc
Products description	Anti-Equine AGP human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Alpha-1 Acid Glycoprotein (AGP), when referred to in the context of equine medicine, becomes a crucial biomarker for assessing inflammation and disease states in horses. Known for its role in the acute phase response, Equine/Horse AGP is a plasma protein that elevates in response to stress, infection, inflammation, and trauma. This biomarker's significance in veterinary practice lies in its sensitivity and specificity to systemic responses, providing invaluable insights into the health status and well-being of equine patients. In horses, AGP levels can serve as an early indicator of disease processes, often before clinical signs become apparent. This feature is particularly beneficial for conditions that may not immediately manifest noticeable symptoms, such as internal inflammations or early stages of infectious diseases. By measuring AGP levels, veterinarians gain a preemptive tool in identifying underlying health issues, allowing for timely intervention and treatment. The role of Equine/Horse AGP extends beyond the mere detection of inflammation. It also plays a pivotal part in monitoring the progression or resolution of a disease. In conditions requiring long-term management or in cases of post-surgical recovery, tracking changes in AGP levels can help veterinarians evaluate the effectiveness of treatments and adjust protocols as necessary. A decline in AGP levels often indicates a positive response to treatment and healing, whereas persistently elevated levels may signal the need for further diagnostic evaluation or a change in therapeutic strategy. Equine AGP is also a valuable prognostic marker. High levels of AGP at the time of diagnosis or during treatment can correlate with more severe disease states and may influence the prognosis. This information is crucial for veterinarians in making informed decisions regarding the care and management of their equine patients, including setting realistic expectations for recovery and outcomes. The measurement of AGP in horses is facilitated by specific assays designed to accurately quantify this protein in equine serum or plasma. The development of these assays reflects the growing recognition of species-specific differences in the acute phase response and the need for targeted diagnostic tools in veterinary medicine. As research in this area advances, the potential for AGP and other biomarkers to contribute to a more nuanced understanding of equine health and disease continues to expand. In summary, Equine/Horse AGP is an essential biomarker in the field of veterinary medicine, offering a window into the systemic health of horses. Its ability to indicate the presence and severity of inflammation and disease, coupled with its utility in monitoring treatment responses, makes AGP a key component of equine healthcare. As veterinary practices evolve with advancements in research and technology, the role of AGP and similar biomarkers in enhancing the diagnosis, treatment, and management of equine diseases is set to grow, furthering the health and welfare of horses worldwide.

About GDU